University of Oulu

Luiro, K., Aittomäki, K., Jousilahti, P., & Tapanainen, J. (2019). Long-term health of women with genetic POI due to FSH-resistant ovaries, Endocrine Connections, 8(10), 1354-1362. Retrieved Apr 21, 2020, from

Long-term health of women with genetic POI due to FSH-resistant ovaries

Saved in:
Author: Luiro, Kaisu1; Aittomäki, Kristiina2; Jousilahti, Pekka3;
Organizations: 1Department of Obstetrics and Gynecology, Reproductive Medicine Unit, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
2Department of Medical Genetics, Helsinki University Hospital, Helsinki, Finland
3Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland
4Department of Obstetrics and Gynecology, University of Oulu and Oulu University Hospital, Medical Research Center, PEDEGO Research Unit, Oulu, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.6 MB)
Persistent link:
Language: English
Published: Bioscientifica, 2019
Publish Date: 2020-04-21


Objective: To study the use of hormone therapy (HT), morbidity and reproductive outcomes of women with primary ovarian insufficiency (POI) due to FSH-resistant ovaries (FSHRO).

Design: A prospective follow-up study in a university-based tertiary clinic setting.

Methods: Twenty-six women with an inactivating A189V FSH receptor mutation were investigated by means of a health questionnaire and clinical examination. Twenty-two returned the health questionnaire and 14 were clinically examined. Main outcome measures in the health questionnaire were reported as HT, morbidity, medication and infertility treatment outcomes. In the clinical study, risk factors for cardiovascular disease (CVD) and metabolic syndrome (MetS) were compared to age-matched controls from a national population survey (FINRISK). Average number of controls was 326 per FSHRO subject (range 178–430). Bone mineral density and whole-body composition were analyzed with DXA. Psychological and sexual well-being was assessed with Beck Depression Inventory (BDI21), Generalized Anxiety Disorder 7 (GAD-7) and Female Sexual Function Index (FSFI) questionnaires.

Results: HT was initiated late (median 18 years of age) compared with normal puberty and the median time of use was shorter (20–22 years) than the normal fertile period. Osteopenia was detected in 9/14 of the FSHRO women despite HT. No major risk factors for CVD or diabetes were found.

Conclusions: HT of 20 years seems to be associated with a similar cardiovascular and metabolic risk factor profile as in the population control group. However, optimal bone health may require an early-onset and longer period of HT, which would better correspond to the natural fertile period.

see all

Series: Endocrine connections
ISSN: 2049-3614
ISSN-E: 2049-3614
ISSN-L: 2049-3614
Volume: 8
Issue: 10
Pages: 1354 - 1362
DOI: 10.1530/EC-19-0244
Type of Publication: A1 Journal article – refereed
Field of Science: 3123 Gynaecology and paediatrics
Funding: This work was financially supported by the Finnish Medical Society (K L), The Sigrid Juselius Foundation (J S T), the Academy of Finland (J S T), the Helsinki University Hospital Research Fund (K L, J S T) and Finska Läkaresällskapet Fund (K A).
Copyright information: © 2019 The authors 2019. This work is licensed under a Creative Commons Attribution 4.0 International License.